Skip to content
Menu

Leerink Partners Maintains Outperform on Benitec Biopharma, Raises Price Target to $18.27

Benzinga Newsdesk 5 days ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Leerink Partners analyst Basma Radwan maintains Benitec Biopharma (NASDAQ:BNTC) with a Outperform and raises the price target from $18 to $18.27.

Leerink Partners analyst Basma Radwan maintains Benitec Biopharma (NASDAQ:BNTC) with a Outperform and raises the price target from $18 to $18.27.

Read at benzinga.com

← All stock news